Lurbinectedin is a chemotherapy drug used to treat small cell lung cancer. The safety of Lurbinectedin for breastfeeding infants is not well established. According to the drug label [3], there is no information on the presence of Lurbinectedin in human milk, the effects on the breastfed infant, or the effects on milk production. Therefore, the use of Lurbinectedin in breastfeeding women is not recommended.

Additionally, the Mayo Clinic [2] states that it is not known whether Lurbinectedin passes into breast milk or if it could harm a nursing baby. It is important to consult with a healthcare provider before using Lurbinectedin while breastfeeding.

DrugPatentWatch [1] provides information on the patents and exclusivity associated with Lurbinectedin, but does not provide any information on its safety for breastfeeding infants.

In summary, the safety of Lurbinectedin for breastfeeding infants is not well established. The drug label and Mayo Clinic recommend against using Lurbinectedin while breastfeeding, and it is important to consult with a healthcare provider before using this drug while breastfeeding.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf